Yep, then the a mod disciple comes to his rescue, of course. Can’t make it up.

So you think Toucan now owns “Advent-Unity” or whatever they decide to call it?

>>Something happened, My bet is value transfer to Advent-Unity.

True, I am pretty absolute about that. Good catch. LOL. Btw, I see none of you care about all of Advent’s cash heading out door. I’m sure you’ll all get your messaging together and regroup for Monday.

Guessing Toucan (LP) took it all? Also 97 mouths to feed in 2024 so how does that work now?

>>Going concern
At the time of approving these financial statements, the director has a reasonable expectation that the Company will have adequate resources to continue operating for the foreseeable future. During the year, the Company wrote off a considerable related party debtor balance which has led to the significant loss. Without this write off, the Company would have had a profit before tax. Thus the director continues to adopt the going concern basis in preparing the financial statements.

>>Ultimate controlling party
At the year end, the company's immediate and ultimate parent undertaking was Toucan Holdings LLC.
Ms L F Powers, the sole director, was also the company's ultimate controlling party at the year end, as she was the person with significant control over Toucan Holdings LLC.
Subsequent to the year end, on 27 August 2025, Toucan Holdings LLC sold its shareholding in the company to Northwest Biotherapeutics Inc, a listed company. Following this transaction, there is no single party with ultimate overall control of the company.
Events after the reporting date
On the 27 August 2025 Advent Bioservices Limited entered into a transaction for the sale of 100% of the Company's share capital to Northwest Biotherapeutics Inc...

“Net income for the year ended 31 December 2024 includes a substantial provision against a related party debtor balance.”

Yep, there it is. Unreal. Sneaky sneaky.

https://find-and-update.company-information.service.gov.uk/company/08717711/filing-history

Damn. Did I miss the 2024 release? Wow, I need to look at that. Thanks. Sure sounds like that’s what she did. Geez.

Never. I lay out possibilities only and assign best guess odds. We maybe never hear from MHRA since they may decide just to keep it nebulous in the interest of all parties.

It sure looked like a great private company heading for the same fate as Cognate. But now it’s looking like she gave shareholders a shell. Very disappointing and outrageous.

He likely knows the UK is playing hot potato with the application.

But we still don’t know yet if shareholders only received a shell or a bonafide CDMO?

She was only there to clean up the SEC mess and as a SEC stipulation, imo. Then she likely took off when the SEC stopped looking.

With the last piece of the puzzle being Advent. I wonder if she knows a SEC inquiry is coming so she gave it back to shareholders?

No CFO - Check.
No real questions ever answered. - Check
No pediatric trial - Check

Also to release LG’s trust from the blocker, but we’ll need to wait to see how that unfolds.

Come on people, just face it, it’s over! Stop with the 2026 pumps. Do you really think Feuerstein would post and STAT would allow those brutal postings if it wasn’t true? No way. Adam knows exactly what’s going on. I’d expect an SEC intervention.

Devastating charge by Feuerstein. Notice that post never made it here until the vote was in. And LP remains utterly silent on it.

Only for an incurious know-it-all such as yourself. It’s a fine line with what Nemesis is claiming and standard procedure with any claim brought by any crank investigated by the NHS Counter Fraud unit. Nemisis could literally submit the claim himself then claim here there’s an investigation (as long as he is in some kind of communication with MHRA) whether there is or not. See how that works?

https://www.bmj.com/content/390/bmj.r1988.full

Nemesis says🤷🏻‍♂️

Still waiting GoodGuyBill.

It’s my hunch there no longer is an agreement between UCLA and NWBO. Each may do what they want with their own proprietary DC formula.

How many months into 2026 with no MHRA news before disciples admit something else is happening?

Just kidding 082, but I do disagree. There’s no point in being a stingy financier with an investment if it’s certain to be a ROI winner. Time is money and nickel and dimeing sometimes comes back to haunt.

>>There is no philanthropy in business as much as you want to believe. They try to squeeze as much as they can. The rest is just lip service! ;)

Clown.

That’s not true. There are financiers out there especially in manufacturing that add to the share price by not only bringing in cash but clients and solid management too. Similar to the groups that sold Cognate for a bundle or the ones who to symbol CDMO for a ride. Then there’s the Woodford’s of the world who just want in.

LOL…The 2026 disappointing calls have begun!!! Is it 2027 yet?🤷‍♀️

Agree. Although given the money that’s been handed over to Advent by way of SOW and allegedly Specials with zero assurance of commercializing, I would not be as forgiving. There’s nothing common about any of this. What’s next up a 10k?

Wouldn’t that be sort of standard procedure with MHRA given the cost involved?

For me now the question is does LP step away and let Advent-Sawston run with various cell and cryo customers attracting shareholder friendly financiers, or is that just all smoke and mirrors too?

Give it up Bio, LP’s had years to take this back to the FDA where they initially sold shareholders on the plan.

2012:

>>markets outside the U.S., where we plan to operate in the future, the prices of medical products are subject to direct price controls and/or to reimbursement with varying price control mechanisms, as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the U.S. Some jurisdictions operate positive and/or negative list systems under which products may only be marketed once a reimbursement price has been agreed. Other countries allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenues and profits.

Suggest in 2026 you start counting down from 900,000,000 and include this quote at the bottom each and every dilution update post. Thank you.

“And we’re not going to do all equity financing, and we certainly hope that our share price is not going to stay at 24, 25 cents. We plan to focus on non-dilutive. So no to the fear mongerers. We are not going to just burn through a whole bunch of shares at a crazy, fast pace.”

You cannot tell me MHRA isn’t helping play the game at this point.

You’ll also note not a word by anyone else but LP during the ASM.🤷‍♀️

Well, at least that’s one of you. My work is done for 2025. 😔

>>100 percent worries about this.

What a way to start the New Year off by ignoring this one! Can’t make it up.

The Top Brain Cancer News of 2025

https://www.targetedonc.com/view/the-top-brain-cancer-news-of-2025

Hey mod, can you please sticky this fresh quote for Dr. Liau. Thanks.

Hey, why not, they just did it with the ASM transcript?🤷‍♀️

Well, GoodGuyBill, we’re still waiting?

Here’s likely how the NICE conversation goes:

You tell us how and why the vaccine seems to help certain patients then back it up with a confirmatory, and we’ll try to green light it for that subset. So long for now.

Here, this is from another biotech’s 10q and it took me one minute to find for you. Now go review NWBO’s 10q and compare the level of detail. Please let us all know what you find.

>>License Agreement with the Baylor College of Medicine
In March 2018, the Company entered into an exclusive license agreement with BCM under which the Company acquired a worldwide, exclusive license to BCM's rights in and to certain intellectual property rights, including a European patent to develop and commercialize MAR-T cell product candidates (the "BCM License Agreement"). In exchange for the license, the Company issued shares of its common stock to BCM valued at approximately $5.0 million at the time of issuance, agreed to make royalty payments to BCM upon commercial sales according to the royalty schedule in the BCM License Agreement, under which the royalty percentages increase in proportion to the aggregate net sales, and agreed to pay BCM certain milestone payments up to an aggregate of $64.85 million. The milestone payments are based upon the occurrence of nine particular milestones relating to completion of the first dosing in clinical trials for a first and second distinct product, FDA approval, and achievement of certain net sales goals. The Company is also responsible for sublicensing fees and for reimbursing BCM for related-party expenses. In addition, upon a liquidity event (as defined in the BCM License Agreement) of the Company, BCM will receive a one-time liquidity incentive payment of 0.5% of the liquidity event proceeds (as defined in the BCM License Agreement).